{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=56", "query": { "intervention": "Formulation #2", "page": 56 }, "page_size": 10 }, "pagination": { "page": 56, "page_size": 10, "total_count": 1745, "total_pages": 175, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=57&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=55&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T20:13:43.471Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04825223", "title": "Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Meningococcal Immunisation", "Healthy Volunteers" ], "interventions": [ { "name": "Multicomponent Meningococcal B Vaccine", "type": "DRUG" }, { "name": "Meningococcal Group B Vaccine MenB", "type": "DRUG" }, { "name": "Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "50 Years", "sex": "ALL", "summary": "42 Days to 50 Years" }, "enrollment_count": 576, "start_date": "2021-03-29", "completion_date": "2022-07-22", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 8, "location_summary": "Guntersville, Alabama • San Diego, California • Tampa, Florida + 5 more", "locations": [ { "city": "Guntersville", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "El Dorado", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04825223" }, { "nct_id": "NCT02504320", "title": "Phase 1, Febuxostat XR Relative Bioavailability Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Febuxostat XR 80 mg Capsule F1", "type": "DRUG" }, { "name": "Febuxostat XR 80 mg Capsule F2", "type": "DRUG" }, { "name": "Febuxostat XR 80 mg Capsule F3", "type": "DRUG" }, { "name": "Febuxostat XR 80 mg Capsule F4", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 78, "start_date": "2015-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-01-19", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02504320" }, { "nct_id": "NCT02005991", "title": "A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-05212377", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 4, "start_date": "2013-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2014-04-16", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 3, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02005991" }, { "nct_id": "NCT00262041", "title": "Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prevention of Meningococcal Disease" ], "interventions": [ { "name": "MenACWY-CRM conjugate vaccine, adjuvanted", "type": "BIOLOGICAL" }, { "name": "MenACWY-CRM conjugate vaccine, unadjuvanted", "type": "BIOLOGICAL" }, { "name": "MenACWY polysaccharide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Vaccines", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "11 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "11 Years to 17 Years" }, "enrollment_count": 524, "start_date": "2004-10", "completion_date": "2006-03", "has_results": true, "last_update_posted_date": "2018-06-28", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 3, "location_summary": "Rochester, Minnesota • Pittsburgh, Pennsylvania • Seattle, Washington", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00262041" }, { "nct_id": "NCT07116031", "title": "A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Graft Versus Host Disease" ], "interventions": [ { "name": "Belumosudil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 37, "start_date": "2025-12-02", "completion_date": "2031-02-28", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 7, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07116031" }, { "nct_id": "NCT02010567", "title": "Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "CRLX101", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2013-12", "completion_date": "2019-06-25", "has_results": true, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 6, "location_summary": "Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02010567" }, { "nct_id": "NCT00635622", "title": "Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacterial Vaginosis" ], "interventions": [ { "name": "LACTIN-V", "type": "DRUG" }, { "name": "Placebo control substance", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Osel, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "FEMALE", "summary": "18 Years to 40 Years · Female only" }, "enrollment_count": 40, "start_date": "2008-04", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2009-07-10", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00635622" }, { "nct_id": "NCT02610777", "title": "An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Leukemia, Myelomonocytic, Chronic", "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2016-04-14", "completion_date": "2021-07-23", "has_results": true, "last_update_posted_date": "2022-09-19", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02610777" }, { "nct_id": "NCT04521231", "title": "A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B Cell Precursor Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 181, "start_date": "2021-01-04", "completion_date": "2029-05-25", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 13, "location_summary": "Clovis, California • Duarte, California • Chicago, Illinois + 10 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04521231" }, { "nct_id": "NCT04138056", "title": "A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Syncytial Virus Infections" ], "interventions": [ { "name": "RSVPreF3 formulation 3", "type": "BIOLOGICAL" }, { "name": "RSVPreF3 formulation 2", "type": "BIOLOGICAL" }, { "name": "Boostrix-ex-US", "type": "BIOLOGICAL" }, { "name": "Boostrix-US", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 509, "start_date": "2019-11-05", "completion_date": "2021-11-22", "has_results": true, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-11-07T20:13:43.471Z", "location_count": 4, "location_summary": "Miami, Florida • Lenexa, Kansas • Rochester, New York + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Rochester", "state": "New York" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04138056" } ] }